Antibiotics produced by Streptomyces

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 5, 2012, Pages 466-471

  de Lima Procópio, Rudi Emerson ^a   da Silva, Ingrid Reis ^a   Martins, Mayra Kassawara ^a   de Azevedo, João Lúcio ^a   de Araújo, Janete Magali ^b  

^a Centro de Biotecnologia da Amazonia CBA   (Brazil)

^b DEPARTAMENTO DE MICOLOGIA   (Brazil)

Author keywords

Antibiotics; Infection; Resistance; Streptomyces

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; GKS 299423; GLYCAN; MACROLIDE; MILBEMYCIN; PEPTIDOGLYCAN; SPECTINOMYCIN; STREPTOMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GENOME; BACTERIAL INFECTION; BACTERIAL MEMBRANE; CELL MEMBRANE PERMEABILITY; DNA REPLICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; GENETIC ANALYSIS; HUMAN; HYDROLYSIS KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN POLYMERIZATION; PROTEIN SYNTHESIS; RNA STABILITY; RNA SYNTHESIS; RNA TRANSCRIPTION; SELF MEDICATION; SHORT SURVEY; STREPTOMYCES; TRANSCRIPTION INITIATION; TRANSLATION REGULATION;

ANTI-BACTERIAL AGENTS; HUMANS; STREPTOMYCES;

EID: 84866883020     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.08.014     Document Type: Short Survey

References (54)

1. Ōmura S., Ikeda H., Ishikawa J., et al. Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc Natl Acad Sci 2001, 98:12215-12220.
2. Khan S.T. Streptomyces associated with a marine sponge Haliclona sp.; biosynthetic genes for secondary metabolites and products. Environ Microbiol Black Sci Pub 2011, 13:391-403.
3. Patzer S.I., Volkmar B. Gene cluster involved in the biosynthesis of griseobactin, a catechol-peptide siderophore of Streptomyces sp. ATCC 700974. J Bacteriol 2010, 192:426-435.
4. Ohnishi Y., Ishikawa J., Hara H., et al. Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350. J Bacteriol 2008, 190:4050-4060.
5. Chater K.F., Chandra G. The evolution of development in Streptomyces analyzed by genome comparisons. FEMS Microbiol Rev 2006, 30:651-672.
6. Chi W.J., Lee S.Y., Lee J.H. Functional analysis of SGR4635-induced enhancement of pigmented antibiotic production in Streptomyces lividans. J Microbiol 2011, 49:828-833.
7. Flärdh K., Buttner M.J. Streptomyces morphogenetics: dissecting differentiation in a filamentous bacterium. Nat 2009, 7:36-49.
8. Ou X., Zhang B., Zhang L., Dong K., Liu C. SarA influences the sporulation and secondary metabolism in Streptomyces coelicolor M145. Acta Biochim Biophys Sin 2008, 40:877-882.
9. Li W., Ying X., Guo Y., et al. Identification of a gene negatively affecting antibiotic production and morphological differentiation in Streptomyces coelicolor A3(2). J Bacteriol 2006, 188:8368-8375.
10. Bentley S.D., Chater K.F., Cerdeño-Tárraga A.M., et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 2002, 417:141-147.
11. Chater K.F., Biró S., Lee K.J., Palmer T., Schrempf H. The complex extracellular biology of Streptomyces. FEMS Microbiol Rev 2010, 34:171-198.
12. Bosso J.A., Mauldin P.D., Salgado C.D. The association between antibiotic use and resistance: the role of secondary antibiotics. Eur J Clin Microbiol Infect Dis 2010, 29:1125-1129.
13. Wang J., Soisson S.M., Young K., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nat 2006, 441:358-361.
14. Bignell D.R.D., Seipke R.F., Huguet-Tapia J.C., Chambers A.H., Parry R.J., Loria R. Streptomyces scabies 87-22 contains a coronafacic acid-like biosynthetic cluster that contributes to plant-microbe interactions. Mol Plant-Microbe Inter 2010, 23:161-175.
15. Barbe V., Bouzon M., Mangenot S., Badet B., et al. Complete genome sequence of Streptomyces cattleya NRRL 8057, a producer of antibiotics and fluorometabolites. J Bacteriol 2011, 193:5055-5056.
16. Watve M.G., Tickoo R., Jog M.M., Bhole B.D. How many antibiotics are produced by the genus Streptomyces?. Arch Microbiol 2001, 176:386-390.
17. Kohanski M.A., Dwyer D.J., Collins J.J. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 2010, 8:423-435.
18. Chopra I., Hesse L., O'Neill A.J. Exploiting current understanding of antibiotic action for discovery of new drugs. J Appl Microbiol 2002, 4S-15S.
19. Brötz-Oesterhelt H., Brunner N.A. How many modes of action should an antibiotic have?. Curr Opin Pharmacol 2008, 8:564-573.
20. Nikaido H. Multidrug Resistance in bacteria. Annu Rev Biochem 2009, 78:119-146.
21. Aminov R.I. The role of antibiotics and antibiotic resistance in nature. Environ Microbiol 2009, 11:2970-2988.
22. Martinez J.L., Fajardo A., Garmendia L., et al. A global viewofantibiotic resistance. FEMS Microbiol Rev 2009, 33:44-65.
23. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol 2010, 8:260-271.
24. Allen H.K., Donato J., Wang H.H., Cloud-Hansen K.A., Davies J., Handelsman J. Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol 2010, 8:251-259.
25. Garza-Ramos U., Silva-Sánchez J., Martínez-Romero E. Genetics and genomics for the study of bacterial resistance. Salud Pública Mex 2009, 51:439-446.
26. Wright G.D. Antibiotic resistance in the environment: a link to the clinic?. Curr Opin Microbiol 2010, 13:589-594.
27. Sheng Q., Jie L., Hua-Hong C., et al. Isolation, diversity, and antimicrobial activity of rare actinobacteria from medicinal plants of tropical rain forests in Xishuangbanna, China. Appl Environ Microbiol 2009, 75:6176-6186.
28. Hassan A., Usman J., Kaleem F., Omair M., Khalid A., Iqbal M. Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis 2011, 15:305-311.
29. Fernandes P. Antibacterial discovery and development - the failure of success?. Nat Biotechnol 2006, 24:1497-1503.
30. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Sci 2009, 325:1089-1093.
31. Simmons K.J., Chopra I., Fishwick C.W.G. Structure-based discovery of antibacterial drugs. Nat Rev Microbiol 2010, 8:501-510.
32. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev 2007, 6:29-40.
33. Freiberg C., Brötz-Oesterhelt H. Functional genomics in antibacterial drug discovery. Drug Discov Today 2005, 10:927-935.
34. Falconer S.B., Brown E.D. New screens and targets in antibacterial drug discovery. Curr Opin Microbiol 2009, 12:497-504.
35. Jones D. The antibacterial lead discovery challenge. Nat Rev Drug Discov 2010, 9:751-752.
36. Dienstmann R., Picoli S.U., Meyer G., Schenkel T., Steyer J. Avaliação fenotípica da enzima Klebsiella pneumoniae carbapenemase (KPC) em Enterobacteriaceae de ambiente hospitalar. J Bras Patol Med Lab 2010, 46:23-27.
37. Tuon F.F., Kruger M., Terreri M., Penteado-Filho S.R., Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. Braz J Infect Dis 2011, 5:594-598.
38. Baumgart A.M.K., Molinari M.A., Silveira A.C.O. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 2010, 14:433-436.
39. Costelloe C., Metcalfe C., Lovering A., Mant D., Hay A.D. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010, 340:c2096.
40. Takesue Y., Nakajima K., Ichki K., et al. Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. J Hosp Infect 2010, 75:28-32.
41. Kiffer C., Hsiung A., Oplustil C., et al. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYS-TIC Program Brazil 2003. Braz J Infect Dis 2005, 9:216-224.
42. Borg M.A., Zarb P., Scicluna E.A., et al. Antibiotic consumption as a driver for resistance in Staphylococcus aureus and Escherichia coli within a developing region. Am J Infect Control 2010, 38:212-216.
43. Sahoo K.C., Tamhankar A.J., Johansson E., Lundborg C.S. Antibiotic use, resistance development and environmental factors: a qualitative study among healthcare professionals in Orissa, India. BMC Public Health 2010, 10:629.
44. Hulscher M.E.J.L., Grol R.P.T.M., Van Der Meer J.W.M. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis 2010, 10:167-175.
45. WHO Global Strategy for Containment of Antimicrobial Resistance 2001, World Health Organization, WHO, Geneva.
46. Lerma F.A., Camerino R.S., Rocha L.A., Colomo O.R. Política de antibióticos en pacientes críticos. Med Intensiva 2010, 34:600-608.
47. st century. Clin Microbiol Infect 2004, 10:10-17.
48. Projan S.J. Why is big pharma getting out of antibacterial drug discovery?. Drug Discov Today 2003, 6:427-430.
49. Boggs A.F., Miller G.H. Antibacterial drug discovery: is small pharma the solution?. Clin Microbiol Infect 2004, 10:32-36.
50. Baltz R.H. Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 2008, 8:557-563.
51. Brazas M.D., Hancock R.E.W. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov Today 2005, 10:1245-1252.
52. Yeh P.J., Hegreness M.J., Aiden A.P., Kishony R. Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 2009, 7:460-466.
53. Butler M.S., Buss A.D. Natural products: the future scaffolds for novel antibiotics?. Biochem Pharmacol 2006, 71:919-929.
54. Brötz-Oesterhelt H., Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 2010, 5:1553-1579.